These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 31648540)

  • 41. Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms.
    Masuda Y; Tatsuno K; Kitano S; Miyazawa H; Ishibe J; Aoshima M; Shimauchi T; Fujiyama T; Ito T; Tokura Y
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1456-1460. PubMed ID: 29341283
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma.
    Ollila TA; Sahin I; Olszewski AJ
    Onco Targets Ther; 2019; 12():1085-1094. PubMed ID: 30799938
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma.
    Shiratori S; Ohhigashi H; Ito S; Kudo K; Adachi M; Minamimoto T; Kato J; Osai Y; Tsutsumi Y; Teshima T
    Hematol Oncol; 2017 Mar; 35(1):138-140. PubMed ID: 26177633
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis.
    Satake A; Konishi A; Azuma Y; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Ito T; Ishii K; Nomura S
    Eur J Haematol; 2020 Dec; 105(6):704-711. PubMed ID: 32564395
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mogamulizumab-associated rash - Case series and review of the literature.
    Hansen I; Abeck F; Menz A; Schneider SW; Booken N
    J Dtsch Dermatol Ges; 2024 Aug; 22(8):1079-1086. PubMed ID: 38924340
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mogamulizumab: first global approval.
    Subramaniam JM; Whiteside G; McKeage K; Croxtall JC
    Drugs; 2012 Jun; 72(9):1293-8. PubMed ID: 22686619
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation.
    Motohashi K; Suzuki T; Kishimoto K; Numata A; Nakajima Y; Tachibana T; Ohshima R; Kuwabara H; Tanaka M; Tomita N; Ishigatsubo Y; Fujisawa S
    Int J Hematol; 2013 Aug; 98(2):258-60. PubMed ID: 23801427
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.
    Ishitsuka K; Yurimoto S; Kawamura K; Tsuji Y; Iwabuchi M; Takahashi T; Tobinai K
    Int J Hematol; 2017 Oct; 106(4):522-532. PubMed ID: 28597329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.
    Zinzani PL; Karlin L; Radford J; Caballero D; Fields P; Chamuleau ME; d'Amore F; Haioun C; Thieblemont C; González-Barca E; García CG; Johnson PW; van Imhoff GW; Ng T; Dwyer K; Morschhauser F
    Haematologica; 2016 Oct; 101(10):e407-e410. PubMed ID: 27418646
    [No Abstract]   [Full Text] [Related]  

  • 50. CCR4 and its ligands: from bench to bedside.
    Yoshie O; Matsushima K
    Int Immunol; 2015 Jan; 27(1):11-20. PubMed ID: 25087232
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma.
    Fujii K; Sakamoto Y; Masaki A; Murase T; Tashiro Y; Yonekura K; Utsunomiya A; Ito A; Kusumoto S; Iida S; Ueda R; Ishida T; Inagaki H
    J Pathol Clin Res; 2021 Jan; 7(1):52-60. PubMed ID: 33022137
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Successful treatment of mogamulizumab-resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment.
    Ohuchi K; Fujimura T; Kambayashi Y; Amagai R; Lyu C; Tanita K; Sato Y; Aiba S
    Dermatol Ther; 2020 Jul; 33(4):e13487. PubMed ID: 32362053
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab.
    Ohuchi K; Fujimura T; Lyu C; Amagai R; Muto Y; Aiba S
    Dermatol Ther; 2020 Nov; 33(6):e14099. PubMed ID: 32725764
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.
    Ishida T; Joh T; Uike N; Yamamoto K; Utsunomiya A; Yoshida S; Saburi Y; Miyamoto T; Takemoto S; Suzushima H; Tsukasaki K; Nosaka K; Fujiwara H; Ishitsuka K; Inagaki H; Ogura M; Akinaga S; Tomonaga M; Tobinai K; Ueda R
    J Clin Oncol; 2012 Mar; 30(8):837-42. PubMed ID: 22312108
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.
    Antoniu SA
    Curr Opin Mol Ther; 2010 Dec; 12(6):770-9. PubMed ID: 21154168
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sézary syndrome managed with histone deacetylase inhibitor followed by anti-CCR4 monoclonal antibody.
    Numata T; Nagatani T; Shirai K; Maeda T; Mae K; Nakasu M; Saito M; Usuda T; Tsuboi R; Okubo Y
    Clin Exp Dermatol; 2018 Apr; 43(3):281-285. PubMed ID: 29327377
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas.
    Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
    Crit Rev Oncol Hematol; 2016 Mar; 99():228-40. PubMed ID: 26811014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.
    Ishida T; Utsunomiya A; Jo T; Yamamoto K; Kato K; Yoshida S; Takemoto S; Suzushima H; Kobayashi Y; Imaizumi Y; Yoshimura K; Kawamura K; Takahashi T; Tobinai K; Ueda R
    Cancer Sci; 2017 Oct; 108(10):2022-2029. PubMed ID: 28776876
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018).
    Kawano N; Yoshida N; Kawano S; Arakawa F; Miyoshi H; Yamada K; Nakashima K; Yoshida S; Kuriyama T; Tochigi T; Nakaike T; Shimokawa T; Yamashita K; Marutsuka K; Mashiba K; Kikuchi I; Ohshima K
    Intern Med; 2019 Aug; 58(15):2159-2166. PubMed ID: 30996180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo.
    Shimizu Y; Koyasu S; Suzukida M; Izumi K; Kidera E; Shindo T; Saga T; Ono M; Takaori-Kondo A; Nakamoto Y
    Ann Nucl Med; 2022 Mar; 36(3):319-326. PubMed ID: 35034259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.